Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.93 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.93 |
| ▸ | PRCP | P42785 | 6/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.49 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium SCHEMBL18066432 | 1.00 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29597389 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29505877 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL29381539 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL574702 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL2303831 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL514422 | 0.98 | TSHR (0.97) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL18066416 | 0.97 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| SCHEMBL18066413 | 0.97 | TSHR (0.93) | TSHRNPSR1PRCPSLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL5439604 | 0.97 | TSHR (1.00) | TSHRNPSR1PRCPSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9802934-B2 | Process for the synthesis of (R)-praziquantel | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-10-31 | — | — | US | disclosed |
| US-9657017-B2 | Crystal form of (R)-praziquantel and preparation method and application thereof | TONGLI BIOMEDICAL CO., LTD. (CN) | 2017-05-23 | — | — | US | disclosed |
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | TONGLI BIOMEDICAL CO., LTD (CN) | 2017-05-04 | — | — | US | disclosed |
| US-20160272636-A1 | CRYSTAL FORM OF (R)-PRAZIQUANTEL AND PREPARATION METHOD AND APPLICATION THEREOF | TONGLI BIOMEDICAL CO., LTD (CN) | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121330-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF (R)-PRAZIQUANTEL | COASY, CYP3A4, CYP4B1 | TSHR 3824/4885NPSR1 2715/4885PRCP 1459/4885 |
| US-20160272636-A1 | CRYSTAL FORM OF (R)-PRAZIQUANTEL AND PREPARATION METHOD AND APPLICATION THEREOF | CYP2C9, CYP1A2, CYP4B1 | TSHR 1879/4885NPSR1 2982/4885PRCP 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.